[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypertensive-intracerebral-hemorrhage\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypertensive-intracerebral-hemorrhage":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100608389","phase-2-a-multicenter-randomized-double-blind-placebo-controlled-trial-on-the-treatment-of-hypertensive-intracerebral-hemorrhage-with-naoxuekang-dropping-pills-100608389",false,"NCT07200921","A Multicenter, Randomized, Double-blind, Placebo-controlled Trial on the Treatment of Hypertensive Intracerebral Hemorrhage With Naoxuekang Dropping Pills","TCM-ICH","Inclusion Criteria:\n\n1. Meets the diagnostic criteria for hypertensive intracerebral hemorrhage.\n2. Able to cooperate with a head MRI examination and has imaging manifestations of cerebral small vessel disease (CSVD) (Staals total CSVD burden score ≥ 1).\n3. Supratentorial hemorrhage (volume ≤ 30ml) or infratentorial hemorrhage (volume ≤ 10ml).\n4. Within 7 days of symptom onset.\n5. NIHSS score ≤ 25.\n6. GCS score ≥ 8.\n7. Age between 18 and 80 years (inclusive).\n8. Any gender\n\nExclusion Criteria:\n\n1. Primary intraventricular hemorrhage.\n2. Spontaneous intracerebral hemorrhage due to other causes or secondary intracerebral hemorrhage (e.g., from trauma, vascular malformations, coagulation disorders, hematological diseases, systemic diseases, or tumors).\n3. Planned surgical intervention (including craniotomy for hematoma evacuation, minimally invasive hematoma removal, or ventricular puncture).\n4. Patients with active peptic ulcer, bleeding, or other clear tendency for rebleeding.\n5. Patients with severe hepatic or renal dysfunction (Severe hepatic dysfunction: ALT or AST \\> 3 times the upper limit of normal; Severe renal dysfunction: Serum creatinine \\> 2 times the upper limit of normal).\n6. Suffering from other life-threatening severe diseases with an expected survival time of less than 1 year.\n7. Known allergy to any component of the study drug.\n8. Pregnant women, women planning pregnancy, or lactating women.\n9. Participating in another interventional clinical trial.","ALL","18 Years","80 Years",{"count":20,"type":21},1950,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This study aims to evaluate the effectiveness and safety of a Chinese medicine-based intervention combined with standard medicine, in reducing composite vascular events in patients with hypertensive intracerebral hemorrhage (HICH).This is a multicenter, randomized, double-blind, placebo-controlled trial. A total of 1950 participants with HICH within 7 days of onset, accompanied by imaging evidence of cerebral small vessel disease, will be enrolled.Participants will be randomly assigned to receive eitherNaoxuekang Dropping Pills or matching placebo for 90 days, in addition to guideline-based standard care.The primary outcome is the incidence of composite vascular events (including ischemic stroke, hemorrhagic stroke, myocardial infarction, vascular death, deep vein thrombosis, and pulmonary embolism) within 1 year.Secondary outcomes include vascular events within 90 days, neurological function (mRS), and cognitive function (MMSE, MoCA) at 90 days and 1 year.Safety will be monitored through adverse event reporting.The results will provide evidence for optimizing secondary prevention strategies in HICH patients.",[27,28],"Hypertensive Intracerebral Hemorrhage","Cerebral Small Vessel Diseases",[30,31,32,33],"Hypertensive intracerebral hemorrhage","Cerebral small vessel disease","Naoxuekang Dropping Pills","Randomized controlled trial","NOT_YET_RECRUITING","2025-09-23",{"date":37,"type":38},"2025-10-01","ACTUAL",{"date":40,"type":21},"2025-10-10",{"date":42,"type":21},"2028-11-30",{"name":44,"class":45},"Beijing Tiantan Hospital","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":54,"targetDuration":56,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":4},"100564940","efficacy-and-safety-study-of-urapidil-alone-or-with-esmolol-in-treating-acute-hypertensive-intracerebral-hemorrhage-100564940","NCT06635707","Efficacy and Safety Study of Urapidil Alone or With Esmolol in Treating Acute Hypertensive Intracerebral Hemorrhage","The Study on the Efficacy and Safety of Using Urapidil Alone or in Combination With Esmolol for the Treatment of Acute Hypertensive Intracerebral Hemorrhage: A Prospective, Open-label, Observational, Multicenter Research","Inclusion Criteria:\n\n1. Participants in the study of acute hypertensive intracerebral hemorrhage aged between 18 and 80 years old;\n2. Participants with acute intracerebral hemorrhage (basal ganglia hemorrhage \\\u003C 50ml) confirmed by imaging within 6 hours of onset;\n3. Participants with systolic blood pressure \\> 140mmHg upon admission;\n4. Participants who have signed the informed consent form.\n\nExclusion Criteria:\n\n1. Participants in the cerebral hemorrhage study who decline to have their disease management information collected and used and\u002For refuse to undergo subsequent follow-ups;\n2. Participants with allergies to the medication in question;\n3. Participants in the study of secondary cerebral hemorrhage resulting from tumors, vascular malformations, aneurysms, trauma, post-thrombolytic therapy, or cerebral arteriovenous thrombosis;\n4. Participants undergoing anticoagulant therapy or with coagulation disorders;\n5. Pregnant women;\n6. Participants with multiple organ failure;\n7. Participants deemed unsuitable for enrollment by the research staff due to other factors.",{"count":55,"type":21},600,"3 Months","OBSERVATIONAL","The objective of this study is to investigate the efficacy and safety of urapidil monotherapy versus the combination of esmolol in treating participants with acute hypertensive intracerebral hemorrhage through a prospective, open-label, observational, multicenter clinical trial, aiming to provide guidance for clinicians in formulating rational treatment plans.",[27],"2024-10-08",{"date":62,"type":38},"2024-10-10",{"date":64,"type":21},"2024-11-01",{"date":66,"type":21},"2026-12-01",{"name":68,"class":45},"Qianfoshan Hospital"]